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Key point 
 Myeloproliferative neoplasm patients have significantly higher symptom burden and lower 
overall quality of life when compared to that of the general population.  
  
Abstract 
Rationale: The myeloproliferative neoplasms (MPNs) including polycythaemia vera (PV), essential 
thrombocythaemia (ET) and primary myelofibrosis (PMF) are rare diseases contributing to 
significant morbidity. Symptom management is a prime treatment objective but current symptom 
assessment tools have not been validated compared to the general population.  
Objectives: The MPN-Symptom Assessment Form (MPN-SAF), a reliable and validated clinical 
tool to assess MPN symptom burden, was administered to MPN patients (n=106) and, for the first 
time, population controls (n=124) as part of a UK pilot case-control study.  Mean symptom scores 
were compared between patients and controls adjusting for potential confounders. Mean patient 
scores were compared to data collected by the Mayo Clinic, USA on 1,446 international MPN 
patients to determine patient group representativeness.  
Results: MPN patients had significantly higher mean scores than controls for 25 of the 26 
symptoms measured (p<0.05); fatigue was the most common symptom (92.4% and 78.1%, 
respectively). Female MPN patients suffered worse symptom burden than male patients (p<0.001) 
and substantially worse burden than female controls (p<0.001).  Compared to the Mayo cohort of 
MPN patients, MPN-UK patients reported similar symptom burden but lower satiety (p=0.046).  
Patients with PMF reported the worst symptom burden (88.3%); significantly higher than PV 
patients (p<0.001). Overall quality of life was impaired in 78.4% MPN-UK patients compared with 
57.4% controls (p<0.001). 
Conclusion:  MPN patients experience significant morbidity compared to the general population 
highlighting the need to manage symptoms effectively.  The results further validate the use of the 
MPN-SAF as a discriminatory tool to assess MPN disease burden.   
Introduction 
The BCR-ABL negative classic myeloproliferative neoplasms (MPNs) which include polycythaemia 
vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) are rare diseases 
with an estimated incidence rate of 0.84, 1.03 and 0.47 per 100,000, respectively1. These 
heterogeneous diseases are characterised by an acquired abnormality of haematopoietic stem cells 
resulting in transformed myeloid progenitor cells which overproduce mature and immature cells 
within the myeloid lineage. Mutations in Janus Kinase 2 (JAK2) and the endoplasmic reticulin 
chaperone calreticulin (CALR) are central to the genetic variability of these diseases which 
contribute to disease pathogenesis, progression and prognosis2, 3.  
 
Symptom burden in MPNs is severe and prevalent in almost all MPN patients contributing to 
significant morbidity4–8. The MPN-symptom assessment form (MPN-SAF) is a clinically validated 
assessment tool which measures 26  symptoms related to MPNs and an overall assessment of 
quality of life (QoL)5. A survey of MPN patients (n=1,179 who are part of the comparison cohort 
included in this report), using the MPN-SAF, identified an array of symptoms including fatigue, 
pruritus and night sweats in 81%, 53% and 50% of patients, respectively4.  Comparison of symptom 
burden across countries has been conducted with overall quality of life, itching and bone pain most 
severe in patients from Italy compared to those from USA or Sweden5.  USA patients reported 
worse fatigue5.  Utilising the European Organisation for Research and Treatment of Cancer Quality 
of Life Questionnaire (EORTC QLQ)-C30 the MPN-SAF showed high correlation for similar 
symptoms.  For PV and ET patients the EORTC QLQ-C30 results resembled those of age and 
gender matched controls while PMF patients displayed worse quality of life5.  Symptom burden, 
assessed using the MPN-SAF, has not yet been assessed in those without MPNs. Many current 
pharmacological treatments for MPN symptoms have side-effects. Understanding the symptom 
burden of MPN patients in comparison to the general population may improve clinical management 
and is of utmost importance.  
 The aim of this study was to determine, for the first time, if the MPN-SAF was able to discriminate 
between symptom burden experienced by MPN patients and that reported in the general population.  
It also aimed to compare symptom burden and overall quality of life reported by MPN patients in 
the UK to those reported internationally.  
 
Methods 
MOSAICC pilot case-control study 
The pilot MOSAICC (Myeloproliferative Neoplasms: An In-depth Case-Control) study aimed to 
identify appropriate methodological approaches to roll-out a UK-wide case-control study of MPNs. 
MPN-UK patients were recruited from two sites: Belfast City Hospital, Belfast, Northern Ireland 
and University Hospital Southampton NHS Foundation Trust, Southampton, England. Eligible 
patients were classified according to the WHO diagnostic criterion9 and identified by their lead 
consultant (MFMcM and ASD).  A study information pack was provided which contained a consent 
form, study information booklet and the MPN-SAF.  Patients were asked to recruit non-blood 
relative or friend controls to the study by providing them with information flyers. Age (5-year age 
band) and gender frequency-matched General Practice controls were recruited by sending a study 
information pack with self-complete MPN-SAF to all controls. The completed MPN-SAFs were 
returned in pre-paid envelopes. Ethical approval was obtained from the Office for Research Ethics 
Committee, Northern Ireland (OREC-NI). MPN-UK patients were receiving standard treatment 
regimens.  
 
Mayo Clinic 
Detailed information on a subset of the patients presented in this paper are described in detail 
elsewhere5, 10.  Briefly, 1,446 MPN-patients were prospectively recruited to participate in an 
assessment of symptom burden at the time of an office visit.  Patients were accrued in academic, 
private, and government-funded medical facilities from approximately November 2009 to January 
2011. The patient survey included questions on demographic and disease-related variables including 
symptom burden assessment via the MPN-SAF. This study included participants from Argentina, 
France, Germany, Italy, the Netherlands, United Kingdom, United States [including Puerto Rico], 
Spain, Sweden, and Uruguay and was administered in seven languages. Once collected by our team 
of international collaborators, data was de-identified and transferred to Mayo Clinic for compilation 
and analysis.  
 
MPN-SAF 
The MPN-SAF is an adaptation of the Myelofibrosis-SAF which includes symptoms common to 
PV and ET patients based on an internet survey. The MPN-SAF has questions regarding: fatigue 
(current, usual, worst in last 24 hours), measured on a scale from 0 (absent) to 10 (worst-
imaginable), and how fatigue affects general activity, mood, walking ability, normal work, relations 
with other people and enjoyment of life, measured on a scale of 0 (Does not interfere) to 10 
(Completely interferes).  In addition questions on early satiety (filling up quickly when you eat), 
abdominal pain, abdominal discomfort, inactivity, problems with headaches, concentration, 
dizziness/vertigo/light headedness, numbness/tingling, difficulty sleeping, depression or sad mood, 
problems with sexual desire or function, cough, night sweats, pruritis (itching), bone pain (diffuse 
not joint pain or arthritis), fever (>37.8oC), unintentional weight lost in last 6 months were measured 
on a scale from 0 (absent) to 10 (worst-imaginable). Finally participants were asked to rate their 
overall quality of life on a scale from 0 (As good as it can be) to 10 (As bad as it can be).  
 
Statistical Analysis 
Symptom prevalence was calculated for all variables by dividing the number of patients reporting a 
score above 1 by all respondents. Mean scores were calculated for each symptom variable and 
standard deviations calculated. Regression analyses were conducted initially comparing symptom 
scores in MPN-UK patients and controls to determine, for the first time, the extent of MPN 
symptoms compared to the general population.  MPN-UK cases were then compared to MPN-Mayo 
patients, adjusting for age (continuous) and gender, to evaluate the representativeness of the 
MOSAICC study MPN patients.  
 
Symptom and overall quality of life scores were categorised into three groups [0 (baseline), 1-5 and 
6-10] and logistic regression analyses utilised to compare symptom burden in MPN-UK patients 
and controls.  Odds ratios (ORs) and 95% confidence intervals (CIs) were adjusted for age, gender, 
education status, presence of a chronic medical condition (heart disease, asthma, diabetes, 
hypertension, psoriasis, hyper/hypothyroidism, rheumatoid arthritis or other self-reported chronic 
condition), smoking (pack years), alcohol consumption (units) and body mass index (current 
weight/height2).  Trend analysis compared MPN-UK patients and controls with regards to each unit 
increase in the symptom score.  
 
Mean symptom scores were calculated for MOSAICC PV, ET and PMF patients respectively and 
for male and female MPN patients and controls.  Symptom scores were compared between male 
and female MPN patients, male and female controls, male MPN patients and male controls and 
female MPN patients and female controls. For all statistical tests a p<0.05 was considered 
statistically significant. Statistical analysis was conducted using STATA 12.0 (Stata-Corp, College 
Station, TX). 
 
Results 
Two hundred and thirty surveys were completed by MOSAICC study participants (106 MPN-UK 
patients, 124 controls) and 1,446 surveys completed by MPN-Mayo patients after excluding those 
without age or gender information available (n=24). Overall, more female MPN-UK patients, UK 
controls and MPN-Mayo patients (60.4%, 62.1% and 54.7%, respectively) than males completed 
the survey.  MPN-UK patients, UK controls and MPN-Mayo patients were of a similar mean age 
(62.2. 60.8 and 63.2 years, respectively).   
 
MPN-UK patients were more likely than controls to report a higher score for all symptoms, with the 
exception of fever, when analyses were adjusted for age and gender, Table 1.  Conversely, both 
patient groups reported similar symptom scores for most variables, Figure 1, with patients from the 
Mayo Clinic study more likely to report early satiety when adjusted for age and gender than MPN-
UK patients (p=0.046) , Table 1.   
 
When comparing symptom burden in MPN-UK patients and controls MPN-UK patients were more 
likely than controls to experience worse fatigue, fatigue affecting general activity, mood, walking 
ability and normal work, enjoyment of life, abdominal pain and discomfort, inactivity, headaches, 
lack of concentration, dizziness, numbness, difficulty sleeping, depression, sexual problems, cough, 
night sweats, pruritus, bone pain, fever, weight loss and overall quality of life, Figure 2/Table 2. All 
symptoms showed an increasing trend per unit increase in score with the exception of relations with 
other people, Table 2.  
 
Of the MPN subtypes PV patients were more likely to report difficulty with lack of concentration, 
sleeping, depression, sexual problems, pruritus and lower overall quality of life than ET and PMF 
patients but differences did not reach statistical significance (data not shown), Figure 1. ET patients 
had the highest burden for mood, relations with other people, headaches and bone pain. PMF 
patients displayed the highest burden for fatigue, fatigue affecting general activity, walking, normal 
work and enjoyment of life, satiety, abdominal discomfort, inactivity, dizziness, numbness, cough, 
night sweats, fever and weight loss, Figure 1. The mean symptom score for cough was significantly 
higher in PMF patients than PV (p=0.039) or ET (p=0.024) patients.  Symptom scores for fever 
were also higher in PMF than PV patients (p=0.050). 
 
Within the pilot MOSAICC study female MPN patients displayed the worst symptom burden for all 
variables with the exception of sexual problems which were more common in male MPN patients, 
Figure 2. Female MPN patients were significantly more likely than male MPN patients to report 
higher mean scores for fatigue, mood, early satiety, headaches, lack of concentration, dizziness, 
difficulty sleeping, depression and night sweats, Table 3.  Female MPN patients were significantly 
more likely than female controls to report higher symptom burden for all variables except fever and 
for overall quality of life.  Quality of life in male MPN patients did not differ to that of male 
controls and there were fewer significant differences compared with females. Male and female 
controls did not report different symptom scores for any of the variables or overall quality of life, 
Table 3. 
 
Discussion       
The MPN-SAF is a clinically validated tool for assessing symptom burden in patients with MPNs. 
For the first time we report the extent of symptoms in MPN patients compared to the general 
population demonstrating the significant burden experienced by MPN patients, particularly females. 
All symptoms assessed were more common in MPN patients than controls, with the expectation of 
‘relations with other people’, after adjusting for potential confounders. Female MPN patients also 
reported a poorer quality of life. Furthermore, symptom burden appeared worst in patients with 
PMF. The MOSAICC study MPN-UK patients reported similar symptom spectrums to those 
previously published by the Mayo Clinic, supporting the use of the MPN-SAF as a valid and 
reliable tool for symptom assessment in other populations5.  
 
The comparison of MPN-UK and MPN-Mayo patients identified ‘early satiety’ as the only 
significantly different symptom with MPN-UK patients less likely to report experiencing early 
satiety. Early satiety is more common in patients with splenomegaly11, which can be  present at 
MPN diagnosis particularly in patients with PMF.  A higher proportion of   PMF patients were 
included in the Mayo Clinic survey (20.4%) compared to the pilot MOSAICC study (13.2%) which 
may explain the observed difference.  Additionally, effective MPN treatment, particularly with the 
newly licensed JAK2 inhibitor Ruxolitinib12, can reduce splenomegaly (present in 10/106 
MOSAICC patients), and associated early satiety13 and usage may differ between countries. 
However, given that all other symptoms were similar between MPN-UK and MPN-Mayo patients 
differences in diet, cultural norms, and portion sizes could contribute.   
 
MPN patients have been shown to have levels of fatigue far in excess of that of published norms4 
but to date no other studies have compared the broad spectrum of MPN symptoms, evaluated by the 
MPN-SAF, with rates in the general population.  Fatigue was the most commonly reported 
symptom among MPN-UK patients consistent with other reports in the literature4, 5, 10, 11, 14, 15.  
Fatigue is a common symptom reported in clinical practice with 58% of patients in primary care 
reporting chronic fatigue16.   Evaluation of fatigue is difficult due to differing levels of patient 
perception and tolerance.  Fatigue correlates with a number of disease measures including time 
since diagnosis, treatment, disease status, complications, comorbidities and lifestyle factors such as 
smoking4.  Male fatigue levels were lower than that of females in both MPN patients and controls.  
However, male MPN-UK patients and male controls reported similar levels of fatigue when 
adjusted for potential confounders while MPN-UK women reported significantly more fatigue that 
female controls.  Further evaluation of these gender differences, particularly in relation to treatment, 
is warranted. In a previous study male patients scored higher than females for experiencing sexual 
problems and weight loss15.  While sexual problems appeared more common in male than female 
MPN patients in the MOSAICC study no significant association was observed.  This could be due 
to the limited sample size included in the pilot study and will be further explored in the planned 
UK-wide study.  However, sexual problems and weight loss were significantly more common in 
male MPN-UK patients than controls.   
 
The extent of symptom burden is an important consideration in the management of MPN patients. 
Clinical response to treatment as set forth by the European Leukemia Net and the International 
Working Group recommends consideration of symptoms when determining complete and partial 
treatment response or clinical improvement17. In their designation, a symptom response is 
represented as greater than 50% reduction in the MPN-SAF total symptom score.  Average five-
year relative survival for PV and ET patients within Europe is 84.8% and 89.9% respectively18.  
Swedish data shows that 32% of PV and 44% of ET patients survive for more than 20 years post 
diagnosis compared to only 6% of PMF patients19. With the emergence of new therapies including 
JAK2 inhibitors20, current trials are not only assessing improvements in the clinical aspects of 
MPNs but on alleviating the symptoms experienced by MPN patients. The COMFORT-I trial, 
which is assessing the effects of the JAK2 inhibitor Ruxolitinib versus placebo and COMFORT-II 
evaluating Ruxolitinib versus best available treatment in PMF patients, have shown marked 
improvement in overall quality of life with improvements in pruritus, night sweats, abdominal 
discomfort, and bone pain21, 22.  However, the symptoms remain higher than those reported by 
controls within this study demonstrating the need for more effective treatments.  Additionally, 
Ruxolitinib, has a number of common side-effects which limit their use.    Ruxolitinib is now 
licensed by the Federal Drug Administration in the USA for Hydroxyurea refractory or intolerant 
PV. Investigation of alternative strategies to alleviate symptoms including fatigue, such as physical 
activity programmes, should be evaluated.  
 
The strengths of this study include the inclusion of a population control group reporting symptoms 
using the validated MPN-SAF questionnaire. This has enabled us to investigate for the first time the 
diverse range of symptoms covered by the MPN-SAF in a non-diseased group.  However, this was a 
pilot investigation and as such the sample size is limited. Expanding the study to a larger number of 
patients and controls will provide a more robust assessment of the discriminatory ability of the 
questionnaire.  Ability to adjust for potential confounding variables such as co-morbidities, smoking 
and alcohol consumption have enabled a more accurate comparison of MPN symptom burden with 
that of controls. Similarities in all symptoms between MPN-UK and MPN-Mayo groups, with the 
exception of early satiety, demonstrate the usefulness of this questionnaire in symptom evaluation.  
The study does recognise the potential limitation of self-reporting bias which may differ between 
patients and controls.  While the study was only administered on one occasion elements of the 
MPN-SAF (including fatigue, early satiety, abdominal pain, abdominal discomfort, inactivity, 
headache, concentration, dizziness, numbness, difficulty sleeping, depression, sexual problems, 
night sweats, pruritus, and bone pain) have been shown to have good correlation on repeat 
measurement5.  MPN patients included in the pilot MOSAICC study were incident and prevalent 
cases (mean duration since diagnosis was 5 years) and evaluation of symptom burden by time since 
diagnosis in comparison to the normative population is warranted.  
 
In conclusion, this study, for the first time compares symptom burden in MPN patients with that of 
controls and acknowledges the manifestation of symptoms and burden in MPN patients and its 
effect on overall quality of life.  Furthermore, this study supports the need for quality of life 
assessment in clinical practice and clinical trial settings to manage and reduce disease burden and 
improve overall patient quality of life.   Fatigue is the most prevalent symptom experience, 
particularly in females, and is an important factor for development of future treatment strategies. 
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Table 1: Percentage of controls and cases reporting symptoms on the MPN-SAF and symptom mean scores.  
 MOSAICC Controls 
(n=124) 
MOSAICC MPN-UK 
patients (n=106) 
MOSAICC 
MPN-UK 
patients vs 
Controls 
p-value* 
MPN-Mayo patients 
(n=1,446) 
MPN-UK vs  
MPN-Mayo 
Patients* 
 
p-value 
Variable/Score Symptom 
Prevalence 
(%) 
Mean Score 
(SD) 
Symptom 
Prevalence 
(%) 
Mean Score 
(SD) 
Symptom 
Prevalence  
(%) 
Mean score 
(SD) 
Fatigue Now 65.1 2.25 (2.32) 83.6 3.72 (2.74)  <0.001 85.3 3.54 (2.55) 0.574 
Fatigue Usual 24 
Hours 
74.0 2.36 (2.12) 90.3 3.89 (2.62)  <0.001 
88.1 3.67 (2.49) 
0.454 
Fatigue Worst 24 
Hours 
78.1 3.40 (2.81) 92.4 4.79 (3.02)  <0.001 
89.8 4.43 (2.81) 
0.264 
General Activity 54.1 1.55 (2.07) 72.1 3.29 (2.89) <0.001 77.9 3.22 (2.67) 0.903 
Mood 58.9 1.76 (2.21) 72.1 2.74 (2.71) <0.001 75.7 2.93 (2.65) 0.477 
Walking ability 44.4 1.18 (2.02) 64.1 2.87 (2.89) <0.001 71.2 2.96 (2.93) 0.599 
Normal Work   54.8 1.56 (2.08) 75.0 3.28 (2.87) <0.001 77.6 3.26 (2.84) 0.959 
Relations 52.4 1.33 (1.88) 54.8 1.88 (2.31) <0.001 66.1 2.33 (2.55) 0.085 
Enjoyment 54.9 1.32 (1.89) 70.2 2.77 (2.66) <0.001 69.2 2.69 (2.79) 0.813 
Early satiety 39.2 1.12 (1.82) 55.7 2.00 (2.50)   0.004 64.7 2.53 (2.76) 0.046 
Abdominal Pain 20.4 0.51 (1.38) 43.8 1.37 (2.10)   0.001 46.5 1.49 (2.26) 0.570 
Abdominal 
Discomfort 
28.5 0.72 (1.52) 54.6 1.90 (2.41) <0.001 
53.4 1.84 (2.44) 
0.861 
Inactivity 29.5 0.92 (1.91) 65.7 2.38 (2.55) <0.001 62.2 2.38 (2.69) 0.900 
Headaches 24.6 0.66 (1.57) 47.6 1.81 (2.72) <0.001 53.3 1.76 (2.42) 0.856 
Concentration 31.4 0.98 (1.99) 63.8 2.45 (2.80) <0.001 64.2 2.54 (2.78) 0.742 
Dizziness 27.7 0.84 (1.71) 63.2 2.25 (2.48) <0.001 57.0 2.02 (2.55) 0.429 
Numbness 23.6 0.78 (1.81) 58.5 2.15 (2.59) <0.001 63.3 2.48 (2.77) 0.208 
Difficulty 
Sleeping 
62.6 2.13 (2.42) 67.0 3.19 (3.16)   0.005 
68.1 3.02 (3.06) 
0.731 
Depression 39.9 1.02 (1.78) 65.1 2.28 (2.46) <0.001 62.4 2.38 (2.71) 0.696 
Sexual Problems 27.8 1.02 (2.14) 56.9 2.96 (3.38)   0.001 61.3 3.16 (3.50) 0.632 
Cough 23.5 0.75 (1.65) 51.9 1.79 (2.41) <0.001 45.9 1.51 (2.29) 0.262 
Night Sweats 30.1 0.96 (1.90) 55.7 2.52 (3.05) <0.001 53.9 2.17 (2.84) 0.224 
Pruritus 21.3 0.70 (1.74) 54.3 2.55 (3.21) <0.001 53.3 2.18 (2.92) 0.230 
Bone Pain 19.7 0.67 (1.85) 50.0 1.91 (2.67) <0.001 49.3 1.96 (2.75) 0.693 
Fever 4.9 0.08 (0.40) 16.0 0.39 (1.32)   0.056 18.0 0.37 (1.14) 0.857 
Weight Loss 6.5 0.24 (1.17) 23.6 0.98 (2.23)   0.006 30.7 1.08 (2.26) 0.638 
Overall Quality of 
life 
57.4 1.47 (1.92) 74.6 2.55 (2.36) <0.001 
78.7 2.87 (2.74) 
0.176 
Symptom prevalence = percentage of participants scoring 1 or higher for each symptom. 
* Regression analysis adjusted for age and gender. 
 Figure 1: Comparison of MPN-UK and MPN-Mayo patient reported symptom scores.  
 
 
Figure 2: Comparison of MOSAICC MPN-UK patient and control reported symptom scores.  
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Symptom
Fatigue Now
Fatigue Usual 24 Hours
Fatigue Worst 24 Hours
General Activity
Mood
Walking
Normal Work
Relations
Enjoyment
Satiety
Abdominal Pain
Abdominal Discomfort
InactivityHeadaches
Concentration
Dizziness
Numbness
Difficulty Sleeping
Depression
Sexual Problems
Cough
Night Sweats
Pruritus
Bone Pain
Fever
Weight Loss
MOSAICC MPN‐UK patients (n=106) MPN‐Mayo patients  (n=1,446)
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Fatigue Now
Fatigue Usual 24 Hours
Fatigue Worst 24 Hours
General Activity
Mood
Walking
Normal Work
Relations
Enjoyment
Satiety
Abdominal Pain
Abdominal Discomfort
Inactivity
HeadachesConcentration
Dizziness
Numbness
Difficulty Sleeping
Depression
Sexual Problems
Cough
Night Sweats
Pruritus
Bone Pain
Fever
Weight Loss
Overall QoL
MOSAICC MPN‐UK patients (N=106) MOSAICC Controls (N=123)
Table 2: Comparison of symptom burden between MOSAICC MPN-UK patients and controls 
adjusted for potential confounding variables. 
Variable 
(Score) 
MPN-UK 
Patients (n) 
 
Controls (n) AOR* (95% CI) 
Fatigue Now 
  No fatigue (0) 
  Some fatigue (1-5) 
  Worst imaginable (6-10) 
  p for trend  
 
17 
59 
28 
 
43 
65 
15 
 
1.00 
2.31 (1.12-4.77) 
5.42 (2.12-13.87) 
<0.001 
Fatigue Usual 24 Hours 
  No fatigue (0) 
  Some fatigue (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
10 
64 
29 
 
32 
75 
16 
 
1.00 
3.84 (1.53-9.67) 
7.29 (2.45-21.67) 
<0.001 
Fatigue Worst 24 Hours 
  No fatigue (0) 
  Some fatigue (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
8 
48 
48 
 
27 
61 
35 
 
1.00 
4.04 (1.48-11.03) 
6.36 (2.26-18.01) 
0.001 
General Activity 
  Does not interfere  (0) 
  Somewhat interferes (1-5) 
  Completely interferes (6-10) 
  p for trend 
 
29 
52 
23 
 
57 
59 
8 
 
 
1.00 
1.85 (0.97-3.51) 
5.17 (1.82-14.68) 
<0.001 
Mood 
  Does not interfere  (0) 
  Somewhat interferes (1-5) 
 
29 
53 
 
51 
62 
 
1.00 
1.63 (0.86-3.10) 
  Completely interferes (6-10) 
  p for trend 
22 11 3.89 (1.47-10.27) 
0.007 
Walking ability 
  Does not interfere  (0) 
  Somewhat interferes (1-5) 
  Completely interferes (6-10) 
  p for trend 
 
37 
42 
24 
 
69 
47 
8 
 
1.00 
1.78 (0.95-3.38) 
4.54 (1.70-12.11) 
<0.001 
Normal Work 
  Does not interfere  (0) 
  Somewhat interferes (1-5) 
  Completely interferes (6-10) 
  p for trend 
 
26 
50 
28 
 
56 
62 
6 
 
1.00 
1.71 (0.88-3.33) 
8.97 (2.95-27.23) 
<0.001 
Relations 
  Does not interfere  (0) 
  Somewhat interferes (1-5) 
  Completely interferes (6-10) 
  p for trend 
 
47 
45 
12 
 
59 
60 
5 
 
1.00 
1.01 (0.56-1.83) 
2.23 (0.64-7.78) 
0.125 
Enjoyment 
  Does not interfere  (0) 
  Somewhat interferes (1-5) 
  Completely interferes (6-10) 
  p for trend 
 
31 
59 
14 
 
56 
61 
7 
 
1.00 
1.82 (0.97-3.41) 
3.38 (1.06-10.80) 
<0.001 
Early satiety 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
47 
45 
14 
 
73 
39 
8 
 
1.00 
1.52 (0.81-2.86) 
2.32 (0.81-6.63) 
0.023 
Abdominal Pain 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
59 
40 
6 
 
98 
21 
4 
 
1.00 
2.98 (1.49-5.97) 
2.44 (0.59-10.10) 
0.004 
Abdominal Discomfort 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
48 
48 
10 
 
88 
31 
4 
 
1.00 
3.00 (1.56-5.77) 
4.56 (1.22-17.02) 
<0.001 
Inactivity 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
36 
56 
13 
 
86 
29 
7 
 
1.00 
4.98 (2.57-9.65) 
3.63 (1.16-11.36) 
<0.001 
Headaches 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
55 
34 
16 
 
92 
27 
3 
 
1.00 
2.45 (1.22-4.92) 
10.04 (2.52-39.96) 
0.001 
Concentration 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
38 
50 
17 
 
83 
31 
7 
 
1.00 
3.60 (1.88-6.89) 
4.87 (1.64-14.48) 
<0.001 
Dizziness 
  Absent (0) 
 
39 
 
89 
 
1.00 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
54 
13 
30 
4 
4.44 (2.28-8.66) 
6.03 (1.71-21.33) 
<0.001 
Numbness 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
44 
47 
15 
 
94 
23 
6 
 
1.00 
3.89 (1.99-7.59) 
5.27 (1.70-16.38) 
<0.001 
Difficulty Sleeping 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
35 
43 
28 
 
46 
63 
14 
 
1.00 
0.91 (0.48-1.75) 
2.32 (0.99-5.43) 
0.015 
Depression 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
37 
54 
15 
 
74 
42 
7 
 
1.00 
2.79 (1.48-5.27) 
4.51 (1.46-13.91) 
<0.001 
Sexual Problems 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
44 
33 
25 
 
88 
27 
7 
 
1.00 
3.02 (1.47-6.18) 
9.34 (3.34-256.08) 
<0.001 
Cough 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
 
51 
44 
11 
 
94 
26 
3 
 
1.00 
3.07 (1.57-5.99) 
6.08 (1.42-26.08) 
  p for trend 0.004 
Night Sweats 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
47 
38 
21 
 
86 
31 
6 
 
1.00 
2.88 (1.43-5.79) 
8.20 (2.76-24.41) 
<0.001 
Pruritus 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
48 
38 
19 
 
96 
21 
5 
 
1.00 
4.16 (2.06-8.40) 
8.79 (2.81-27.44) 
<0.001 
Bone Pain 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
53 
40 
13 
 
 
98 
19 
5 
 
1.00 
4.63 (2.20-9.75) 
5.07 (1.51-17.05) 
0.001 
Fever 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
89 
14 
3 
 
117 
6 
0 
 
1.00 
3.86 (1.27-11.75) 
- 
0.047 
Weight Loss 
  Absent (0) 
  Moderate (1-5) 
  Worst imaginable (6-10) 
  p for trend 
 
81 
17 
8 
 
115 
5 
3 
 
1.00 
5.84 (1.90-17.96) 
2.05 (0.43-9.74) 
0.015 
Overall Quality of life    
  As good as it can be (0) 
  Moderate (1-5) 
  As bad as it can be (6-10) 
  p for trend 
27 
68 
11 
 
52 
64 
6 
1.00 
2.22 (1.15-4.30) 
3.04 (0.88-10.46) 
0.003 
*AOR (Adjusted Odds Ratio) and 95% CI (Confidence Interval) per point increase in response 
variable adjusted for age, gender, education status, presence of a chronic medical condition (heart 
disease, asthma, diabetes, hypertension, psoriasis, hyper/hypothyroidism or rheumatoid arthritis), 
smoking (pack years), alcohol consumption (units) and body mass index. 
p for trend is per unit increase in symptom variable/quality of life score. 
 Figure 1: Mean symptom scores in MOSAICC cases by myeloproliferative neoplasm subtype.  
PV= polycythaemia vera, ET=essential thrombocythaemia, PMF=primary myelofibrosis 
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Figure 2: Mean symptom scores in MOSAICC cases and controls by gender.  
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Table 3: T-tests comparing symptom scores between male and female MOSAICC cases and controls 
Variable Male vs Female Cases 
p-value 
Male vs Female Controls 
p-value 
Male cases vs Male controls 
p-value 
Female cases vs female controls 
p-value 
Fatigue Now 0.029 0.570 0.271 <0.001 
Fatigue Usual 24 Hours 0.070 0.987 0.068 <0.001 
Fatigue Worst 24 Hours 0.037 0.757 0.261 <0.001 
General Activity 0.244 0.363 0.047 <0.001 
Mood 0.010 0.763 0.647 <0.001 
Walking 0.375 0.545 0.026 <0.001 
Normal Work 0.135 0.338 0.080 <0.001 
Relations 0.135 0.305 0.832 0.009 
Enjoyment 0.122 0.506 0.113 <0.001 
Early satiety 0.068 0.495 0.643 <0.001 
Abdominal Pain 0.475 0.143 0.261 <0.001 
Abdominal Discomfort 0.198 0.596 0.093 <0.001 
Inactivity 0.186 0.857 0.027 <0.001 
Headaches <0.001 0.148 0.320 <0.001 
Concentration 0.006 0.387 0.087 <0.001 
Dizziness 0.013 0.718 0.055 <0.001 
Numbness 0.274 0.735 0.026 <0.001 
Difficulty Sleeping 0.005 0.247 0.523 0.002 
Depression 0.006 0.621 0.169 <0.001 
Sexual Problems 0.243 0.113 0.001 <0.001 
Cough 0.666 0.444 0.088 <0.001 
Night Sweats 0.011 0.141 0.040 <0.001 
Pruritus 0.190 0.673 0.019 <0.001 
Bone Pain 0.086 0.298 0.330 <0.001 
Fever 0.971 0.934 0.139 0.057 
Weight Loss 0.805 0.885 0.037 0.017 
Overall Quality of life 0.077 0.844 0.223 <0.001 
 
 
